← Leaderboards
Christopher L. Cioffi
Columbia University Health Sciences
$3,409,772
Attributed
$7,447,350
Total exposure
5
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,447,350 · 5
By mechanism
R01$5,560,343 · 3
R61$1,418,507 · 1
R21$468,500 · 1
Top collaborators
- Konstantin Petrukhin11 shared
- Robert John Vandenberg4 shared
- Gennadiy Moiseyev3 shared
Most similar at Columbia University Health Sciences
Same institution · by research overlap
- Elizabeth M Bradshaw$11,004,520
- Davangere P Devanand$43,591,695
- Konstantin Petrukhin$4,542,112
- Gennadiy Moiseyev$2,581,356
- Wassim Elyaman$6,169,565
Others in their field
Other Emerging Leaders on “Property”
- Valerie Koch · University Corporation For Atmospheric Res$247,762,266
- Susan Abushakra · Alzheon, Inc.$47,265,244
- John Hobbs · Suny At Stony Brook$42,194,917
- Christopher Bee · Suny At Stony Brook$41,239,084
- John Damon Chodera · Sloan-Kettering Inst Can Research$39,689,447
- Eric C Palm · Florida State University$35,115,872
Research focus
PropertyIn VivoIn VitroCharacteristicsDosePharmaceutical PreparationsAnalogPharmaceutical ChemistryTissuesClinical TrialsSafetyMetabolismAbsorptionSpecificityPre-ClinicalEvaluationBindingOralExperimental StudyDesignGeneral PopulationExtracellularPharmacologyExhibits
Grant awards (15)
Advancing the small molecule drug candidate with dual specificity as a therapy for dry AMD$644,338
R61 · FY2025 · EY
Polypharmacological approach to treatment of Stargardt disease$619,139
R01 · FY2025 · EY
Pharmacological modulation of ion currents for treatment of exfoliation glaucoma$205,625
R21 · FY2025 · EY
Advancing the small molecule drug candidate with dual specificity as a therapy for dry AMD$774,169
R61 · FY2024 · EY
Polypharmacological approach to treatment of Stargardt disease$619,139
R01 · FY2024 · EY
Pharmacological modulation of ion currents for treatment of exfoliation glaucoma$262,875
R21 · FY2024 · EY
Polypharmacological approach to treatment of Stargardt disease$645,138
R01 · FY2023 · EY
Discovery and development of novel glycine transporter-2 inhibitors for the treatment of neuropathic pain$455,166
R01 · FY2022 · DA · contact PI
Novel therapies for macular degeneration, transthyretin amyloidosis and their common age-related comorbidities$383,990
R01 · FY2022 · EY
Discovery and development of novel glycine transporter-2 inhibitors for the treatment of neuropathic pain$430,744
R01 · FY2021 · DA · contact PI
Pharmacological treatment for atrophic age-related macular degeneration compounded by common forms of age-related amyloid disease$479,015
R01 · FY2020 · EY
Discovery and development of novel glycine transporter-2 inhibitors for the treatment of neuropathic pain$420,857
R01 · FY2020 · DA · contact PI
Discovery and development of novel glycine transporter-2 inhibitors for the treatment of neuropathic pain$534,125
R01 · FY2019 · DA · contact PI
Pharmacological treatment for atrophic age-related macular degeneration compounded by common forms of age-related amyloid disease$479,015
R01 · FY2019 · EY
Pharmacological treatment for atrophic age-related macular degeneration compounded by common forms of age-related amyloid disease$494,015
R01 · FY2018 · EY